Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma
{{output}}
Introduction: Chimeric antigen receptor (CAR) T-cell therapies have rapidly become an integral part of the treatment landscape for relapsed or refractory lymphomas. While early clinical trials demonstrated impressive response rat... ...
